| Pharmaceutical trademarks: navigating through the FDA's pilot program. | |
| | |
MedLine Citation:
|
PMID: 20603657 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Creation and clearance of pharmaceutical trademarks continues to be one of the most difficult and challenging areas of trademark law. The Food and Drug Administration (FDA) recently initiated a 2-year Pilot Program under Prescription Drug User Fee Act (PDUFA) IV. The intent of the program is to enable participating pharmaceutical firms to evaluate proposed pharmaceutical marks and submit the data generated from those evaluations to the FDA for review. Submitting a trademark to the FDA warrants questions: What supporting data is needed and accepted when proposing a mark? What issues might arise, and how can they be averted? In a recent Thomson Reuters on-demand webinar (http://science.thomsonreuters.com/news/2010-02/8580404/), a group of renowned experts in the field of trademark development review the FDA pilot program, outline the requirements for submission and discuss what the changes will mean in clearing new pharmaceutical marks. They also present various approaches to trademark development and evaluation in light of the FDA's views. |
| | |
Authors:
|
Elisa Ferrer |
Related Documents
:
|
11010327 - Evaluation of knowledge using exame program on the internet. 8689097 - Making sense of symptoms: self-categorization and the meaning of illness and injury. 19494167 - Evaluation of a cognitive intervention program for juvenile offenders. 12705467 - Tracking process and outcome results of bsw students' preparation for public child welf... 11029847 - Case study using descriptive analysis to estimate hidden costs in processing third part... 3749917 - Radiation protection programs in nuclear medicine. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Drug news & perspectives Volume: 23 ISSN: 0214-0934 ISO Abbreviation: Drug News Perspect. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-07-06 Completed Date: 2010-10-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8809164 Medline TA: Drug News Perspect Country: United States |
Other Details:
|
Languages: eng Pagination: 333-6 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2010 Prous Science, S.A.U. or its licensors. All rights reserved. |
Affiliation:
|
ferrer.elisa@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Drug Approval Drug Prescriptions / standards Legislation, Drug / trends* Patents as Topic / legislation & jurisprudence* Pharmaceutical Preparations* Pilot Projects Terminology as Topic United States United States Food and Drug Administration* |
| Chemical | |
Reg. No./Substance:
|
0/Pharmaceutical Preparations |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: CYBA gene variants as biomarkers for coronary artery disease.
Next Document: Detailed voltammetric and EPR study of protonation reactions accompanying the one-electron reduction...